Cargando…

Periodontal Therapy with 0.25%Lemongrass Oil Mouthwash in Reducing Risk of Cardiovascular Diseases: A 3-Arm Prospective Parallel Experimental Study

BACKGROUND: Periodontal disease is associated with cardiovascular diseases because of its role in host immune-inflammatory response. Serum lipids are the commonest risk factors between periodontal disease and cardiovascular diseases. MATERIALS AND METHOD: A double blinded randomised clinical trial w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subha, Dany S, Pradeep, Tangde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research and Publications Office of Jimma University 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615015/ https://www.ncbi.nlm.nih.gov/pubmed/29217959

Ejemplares similares

Anti-Plaque and Anti-Gingivitis Efficacy of 0.25% Lemongrass Oil and 0.2% Chlorhexidine Mouthwash in Children
por: Akula, Sreekumar, et al.
Publicado: (2021)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

Lemongrass essential oil gel as a local drug delivery agent for the treatment of periodontitis
por: Warad, Shivaraj B., et al.
Publicado: (2013)

Caudal Epidural Analgesia in Pediatric Patients: Comparison of 0.25% Levobupivacaine and 0.25% Ropivacaine in Terms of Motor Blockade and Postoperative Analgesia
por: Praveen, P., et al.
Publicado: (2017)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

A Comparative Study of Effect of 0.25% Levobupivacaine with Dexmedetomidine versus 0.25% Levobupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block
por: Iyer, Lakshmi S., et al.
Publicado: (2021)

Exchange-bias via nanosegregation in novel Fe(2−x)Mn(1+x)Al (x = −0.25, 0, 0.25) Heusler films
por: Kurdi, S., et al.
Publicado: (2020)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

Potential outstanding physical properties of novel black arsenic phosphorus As(0.25)P(0.75)/As(0.75)P(0.25) phases: a first-principles investigation
por: Liu, Fangqi, et al.
Publicado: (2022)

Lemongrass Essential Oil Components with Antimicrobial and Anticancer Activities
por: Mukarram, Mohammad, et al.
Publicado: (2021)

KNb(1.75)V(0.25)PS(10)
por: Yu, Jaemin, et al.
Publicado: (2011)

Treatment of angiokeratomas of Fordyce with topical rapamycin 0.25% cream
por: Bell, Katheryn A., et al.
Publicado: (2020)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

The CMS tracker APV25 $0.25 \mu m$ CMOS readout chip
por: Raymond, M, et al.
Publicado: (2000)

Polylactic Acid—Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties
por: Liakos, Ioannis L., et al.
Publicado: (2016)

1-Benzyl-3-methylimidazolium chloride 0.25-hydrate
por: Ji, Xiujie, et al.
Publicado: (2009)

Possible quadrupole-first options with $\beta^* \leq$ 0.25M
por: Koutchouk, Jean-Pierre
Publicado: (2006)

Standard of Spectral Radiance for the Region of 0.25 to 2.6 Microns
por: Stair, Ralph, et al.
Publicado: (1960)

Experiments on MEMS Integration in 0.25 μm CMOS Process
por: Michalik, Piotr, et al.
Publicado: (2018)

Cataract Surgery by Intraoperative Surface Irrigation with 0.25% Povidone–Iodine
por: Shimada, Hiroyuki, et al.
Publicado: (2021)

4-(3-Methylanilino)-N-[N-(1-methylethyl)carbamoyl]pyridinium-3-sulfonamidate (torasemide) methanol 0.25-solvate 0.25-hydrate
por: Bartolucci, Gianluca, et al.
Publicado: (2009)

Ultrasound guided peritubal infiltration of 0.25% Bupivacaine versus 0.25% Ropivacaine for postoperative pain relief after percutaneous nephrolithotomy: A prospective double blind randomized study
por: Parikh, Geeta P, et al.
Publicado: (2014)

Wall-plug power of 2x0.25 TeV CLIC
por: Hübner, K
Publicado: (1992)

3,4-Dinitro-1H-pyrazole benzene 0.25-solvate
por: Li, Yong-Xiang, et al.
Publicado: (2011)

2,3,4-Trihydroxybenzoic acid 0.25-hydrate
por: Li, Jin-Hang, et al.
Publicado: (2012)

Wall-plug power of 2x0.25 TeV CLIC
por: Hübner, K
Publicado: (1992)

Design of a comparator in a 0.25 $\mu m$ CMOS technology
por: Van Bakel, N, et al.
Publicado: (2000)

The 0.25um Token Bit Manager Chip for the CMS Pixel Readout
por: Bartz, Edward
Publicado: (2005)

Antimicrobial Lemongrass Essential Oil—Copper Ferrite Cellulose Acetate Nanocapsules
por: Liakos, Ioannis L., et al.
Publicado: (2016)

Cardiovascular and respiratory effects of lumbosacral epidural bupivacaine in isoflurane-anesthetized dogs: The effects of two volumes of 0.25% solution
por: Dias, Raquel Sartori Gonçalves, et al.
Publicado: (2018)

Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia: A Pilot, Randomized Open-Label Study
por: Bharadwaj, Apoorva V, et al.
Publicado: (2023)

Alfentanil-bupivacaina al 0.125 % vs. bupivacaina al 0.25 % en analgesia obstétrica.
por: Santiago Poot, Noemi
Publicado: (1994)

Bupivacaina al 0.25 versus 0.125% para analgesia obstétrica en pacientes primigestas
por: Reyes González, Rosa Isela
Publicado: (1998)

First-Principles Study of Bi-Doping Effects in Hg(0.75)Cd(0.25)Te
por: Sun, Xueli, et al.
Publicado: (2021)

The ATLAS pixel front end chip FEI in 0.25$\mu$m technology
por: Fischer, P
Publicado: (2002)

Noise characterization of a 0.25 $\mu$ m CMOS technology for the LHC experiments
por: Anelli, G, et al.
Publicado: (2001)

Arthroscopic and Low-Field MRI (0.25 T) Evaluation of Meniscus and Ligaments of Painful Knee
por: Lokannavar, Harish S, et al.
Publicado: (2012)

Tenulin 0.25-hydrate, a sesquiterpene lactone isolated from Helenium amarum
por: Knight, Kyle S., et al.
Publicado: (2013)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q44dv2fgu06c9sl62ipkt1amg4